Literature DB >> 12880926

Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates.

Andre J Marozsan1, Eric J Arts.   

Abstract

A recent shift from studies on a few subtype B laboratory human immunodeficiency virus type 1 (HIV-1) clones to analyses of extremely diverse primary HIV-1 isolates from different subtype requires the development of a rapid and generic cloning technique. This report describes the use of gap repair/recombination in yeast to shuttle env, gag, and pol genes from diverse HIV-1 subtypes into a DNA vector that can be amplified in bacteria and can express the gene of interest in mammalian cells. These diverse HIV-1 genes have also been introduced into an infectious clone to produce chimeric viruses that are useful for studies on drug susceptibility, receptor binding and fitness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880926     DOI: 10.1016/s0166-0934(03)00166-6

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  19 in total

1.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

2.  Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrin.

Authors:  Behzad Etemad; Oscar A Gonzalez; Sean McDonough; Victor Pena-Cruz; Manish Sagar
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

3.  Measuring HIV fusion mediated by envelopes from primary viral isolates.

Authors:  Marielle Cavrois; Jason Neidleman; Nicole Galloway; Cynthia A Derdeyn; Eric Hunter; Warner C Greene
Journal:  Methods       Date:  2010-06-08       Impact factor: 3.608

4.  Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Authors:  Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

6.  Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques.

Authors:  Dawn M Dudley; Jennifer L Wentzel; Matthew S Lalonde; Ronald S Veazey; Eric J Arts
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

7.  In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Authors:  Athe M N Tsibris; Manish Sagar; Roy M Gulick; Zhaohui Su; Michael Hughes; Wayne Greaves; Mani Subramanian; Charles Flexner; Françoise Giguel; Kay E Leopold; Eoin Coakley; Daniel R Kuritzkes
Journal:  J Virol       Date:  2008-05-21       Impact factor: 5.103

8.  Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication.

Authors:  Yong Gao; Michael A Lobritz; Justin Roth; Measho Abreha; Kenneth N Nelson; Immaculate Nankya; Dawn M Moore-Dudley; Awet Abraha; Stanton L Gerson; Eric J Arts
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

9.  Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.

Authors:  Michael A Lobritz; Andre J Marozsan; Ryan M Troyer; Eric J Arts
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

10.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.